Literature DB >> 1115660

Levodopa-induced postural hypotension. Treatment with fludrocortisone.

M M Hoehn.   

Abstract

Six parkinsonian patients with symptomatic postural hypotension secondary to levodopa therapy were treated with 0.05 to 0.2 mg of fludrocortisone acetate daily for six to ten months. Severe orthostatic light-headedness and frequent syncope had previously been alleviated only be reducing the dosage of levodopa to levels producing less than optimal antiparkinsonian benefits. In all six patients, symptoms were alleviated satisfactorily, and supine and upright blood pressures returned to normal levels during treatment with fludrocortisone acetate. There were no adverse reactions. Fludrocortisone acetate is an effective and safe drug for the treatment of severe and otherwise intractable postural hypotension secondary to therapy with levodopa.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1115660     DOI: 10.1001/archneur.1975.00490430072013

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  14 in total

1.  Early discontinuation of treatment in patients with orthostatic hypotension.

Authors:  C Shibao; C G Grijalva; L A Lipsitz; I Biaggioni; M R Griffin
Journal:  Auton Neurosci       Date:  2013-08-20       Impact factor: 3.145

2.  The protein Ocular albinism 1 is the orphan GPCR GPR143 and mediates depressor and bradycardic responses to DOPA in the nucleus tractus solitarii.

Authors:  Y Hiroshima; H Miyamoto; F Nakamura; D Masukawa; T Yamamoto; H Muraoka; M Kamiya; N Yamashita; T Suzuki; S Matsuzaki; I Endo; Y Goshima
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 3.  The Pharmacology of Autonomic Failure: From Hypotension to Hypertension.

Authors:  Italo Biaggioni
Journal:  Pharmacol Rev       Date:  2017-01       Impact factor: 25.468

Review 4.  Clinical Relevance of Orthostatic Hypotension in Neurodegenerative Disease.

Authors:  Katherine E McDonell; Cyndya A Shibao; Daniel O Claassen
Journal:  Curr Neurol Neurosci Rep       Date:  2015-12       Impact factor: 5.081

Review 5.  Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease.

Authors:  Lindy D Wood
Journal:  Drugs Aging       Date:  2010-04-01       Impact factor: 3.923

Review 6.  Pharmacotherapy of autonomic failure.

Authors:  Cyndya Shibao; Luis Okamoto; Italo Biaggioni
Journal:  Pharmacol Ther       Date:  2011-06-12       Impact factor: 12.310

Review 7.  Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management.

Authors:  J M Senard; C Brefel-Courbon; O Rascol; J L Montastruc
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 8.  Pharmacotherapy of Cardiovascular Autonomic Dysfunction in Parkinson Disease.

Authors:  Cyndya A Shibao; Horacio Kaufmann
Journal:  CNS Drugs       Date:  2017-11       Impact factor: 5.749

9.  Orthostatic hypotension as an early finding in Parkinson's disease.

Authors:  David S Goldstein
Journal:  Clin Auton Res       Date:  2006-02       Impact factor: 4.435

10.  Twenty-four hour non-invasive ambulatory blood pressure and heart rate monitoring in Parkinson's disease.

Authors:  Eva Stuebner; Ekawat Vichayanrat; David A Low; Christopher J Mathias; Stefan Isenmann; Carl-Albrecht Haensch
Journal:  Front Neurol       Date:  2013-05-15       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.